Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics.

Malik, Bilal; Bartlett, Nathan W; Upham, John W; Nichol, Kristy S; Harrington, John; Wark, Peter A B

Malik, Bilal; Bartlett, Nathan W; Upham, John W; Nichol, Kristy S; Harrington, John; Wark, Peter A B.

Afiliação

Malik B; Immune Health Program, Hunter Medical Research Institute, University of Newcastle, Callaghan, New South Wales, Australia.
Bartlett NW; Immune Health Program, Hunter Medical Research Institute, University of Newcastle, Callaghan, New South Wales, Australia.
Upham JW; Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Nichol KS; Immune Health Program, Hunter Medical Research Institute, University of Newcastle, Callaghan, New South Wales, Australia.
Harrington J; Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton Heights, New South Wales, Australia.
Wark PAB; Immune Health Program, Hunter Medical Research Institute, University of Newcastle, Callaghan, New South Wales, Australia.

Respirology ; 28(8): 758-766, 2023 08.

Article em En | MEDLINE | ID: mdl-37114915

Assuntos

Asma; Produtos Biológicos; Eosinofilia Pulmonar; Humanos; Imunidade Inata; Interleucina-13; Omalizumab; Interleucina-5; Interleucina-6; Linfócitos; Asma/tratamento farmacológico; Citocinas/metabolismo; Proliferação de Células

Palavras-chave

ILC2; mepolizumab; omalizumab; proliferation; severe asthma; thymic stromal lymphopoietin receptor; type 2 cytokine; type 2 innate lymphoid cell

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Eosinofilia Pulmonar / Asma / Produtos Biológicos Limite: Humans Idioma: En Revista: Respirology Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google